Search

everythinglearnresearchcommunity

for

Search:↓

Eyebrow hair transplants in patients with frontal fibrosing alopecia may look good at first but often lose the new hair after a few years.

Sandalore®, a synthetic scent, improved hair loss and satisfaction in women with telogen effluvium.

Many patients with autoimmune blistering skin disorders change their diets, avoiding foods like alcohol, citrus, and spices, and some find vegetables and dairy helpful.

Up to half of people experience itchy scalp, often due to skin conditions like seborrheic dermatitis or psoriasis, and treatments vary based on the specific cause.

New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.

The electronic version of the Dermatology Life Quality Index is as effective as the paper version, with most patients preferring it.

Transgender patients on hormone therapy experience more acne and hair loss, but less skin inflammation.

Genes controlling hair growth and immune response are disrupted in male pattern baldness.

Bimekizumab effectively treats scalp cellulitis and improves quality of life.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Belimumab effectively controls SLE disease activity and reduces steroid use.

Brodalumab is more effective than ustekinumab in treating psoriasis.

COVID-19 can cause skin issues like "COVID toes," rashes, hair loss, and hand eczema, and dermatologists are important for recognizing these signs.

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

3D imaging effectively tracks skin changes in vitiligo treatment.

Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.